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ABSTRACT  
Objective 
To determine whether intensive combinations of synthetic disease modifying drugs 
(cDMARDS) achieve similar clinical benefits more cheaply than high-cost biologics such as 
tumour necrosis factor inhibitors (TNFis) in patients with active rheumatoid arthritis (RA) 
who have failed to respond to methotrexate and another DMARD. 
Methods 
Within-trial, cost-effectiveness and cost-utility analyses from health and social care (H&SC) 
and two societal perspectives. Participants were recruited into an open-label, 12-month, 
pragmatic, randomised, multicentre, two-arm, non-inferiority trial in 24 rheumatology 
clinics in England. Costs were linked with the Heath Assessment Questionnaire (HAQ; 
primary outcome) and quality-adjusted life years (QALYs) derived from two measures (SF-
36, EQ-5D-3L). 
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Results 
205 participants were recruited, 104 in the cDMARDs arm, 101 in the TNFis arm. cDMARD 
arm participants with poor response at 6 months were offered TNFis; 46 (44%) switched. 
Relevant cost and outcome data were available for 93% of participants at 6 month follow-up 
and 91-92% at 12 month follow-up. The cDMARDs arm had significantly lower total costs 
from all perspectives (6 month H&SC adjusted mean difference -£3615 (95% confidence 
interval -£4104 to -£3182); 12 month H&SC adjusted mean difference -£1930 (95% 
confidence interval -£2599 to -£1301)). The HAQ showed benefit to the cDMARDs arm at 12 
months (-0.16; 95% CI-0.32 to -0.01); other outcomes/follow-ups showed no differences.  
Conclusion 
Starting treatment with cDMARDs, rather than TNFis, achieves similar outcomes at 
significantly lower costs. Patients with active rheumatoid arthritis and meeting NICE criteria 
for expensive biologics can cost-effectively be treated with combinations of intensive 
synthetic disease modifying drugs. 
 
KEY WORDS 
Rheumatoid Arthritis; Economic evaluations; Anti-TNF; DMARDs. 
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SIGNIFICANCE AND INNOVATIONS 
 
 Our results show that cDMARDs are a more cost-effective treatment approach for 
RA as the cDMARDs group achieved similar outcomes compared with the TNFi group 
at significantly lower costs. This is important in the context of ongoing cost-
effectiveness and affordability concerns regarding the use of biologics. 
 
 High quality cost-effectiveness evidence is vital to inform resource allocation 
decisions. These results are based on a robust, comprehensive and prospective trial-
based economic evaluation in the context of an evidence base thus far dominated by 
modelling studies. 
 
Rheumatoid arthritis (RA) is a common long-term inflammatory disorder affecting 0.5-1% 
adults in industrialised countries,[1] characterised by persisting joint inflammation. 
Consequences span erosive joint damage, systemic comorbidities like cardiovascular 
disease[2] with consequent reductions in life expectancy[2], persisting disability and 
reduced quality of life[3], and high medical and societal costs.[4] 
 
Joint inflammation in RA is treated by methotrexate and other conventional Disease-
Modifying Anti-Rheumatic Drugs (DMARDs). If methotrexate proves insufficient more 
intensive treatments are used, including combinations of conventional DMARDs[5] 
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(previously demonstrated as likely to be cost-effective compared with DMARD 
monotherapy),[6] and biologic drugs like Tumour Necrosis Factor inhibitors (TNFis). Both 
approaches are clinically effective. While biologics show promise of cost-effectiveness as 
part of a treatment escalation approach,[7] they are nevertheless substantially more 
expensive and carry ongoing cost-effectiveness[8] and affordability concerns; 
methodological nuances also add to uncertainty over their cost-effectiveness.[8]  
 
In the TACIT trial, we compared clinical and economic outcomes of two intensive treatment 
strategies in patients with active RA who have failed to respond to methotrexate and 
another DMARD. One strategy was based on initially using combinations of conventional 
DMARDs (cDMARDs), using biologics only if patients failed to respond after 6 months. The 
other strategy was based on starting biologic therapy with tumour necrosis factor inhibitors 
(TNFis). Clinical outcomes showed starting with combinations of cDMARDs gave non-inferior 
clinical outcomes to starting with TNFis9. We now report the associated pre-planned 
economic evaluation. 
 
MATERIALS AND METHODS 
Design and Intervention 
The TACIT trial was an open-label, 12-month, pragmatic, randomised, multicentre, two-arm, 
non-inferiority trial comparing two treatment strategies for RA patients - one starting with 
cDMARDS, the other with TNFis.[9] Recruitment started on 1 April 2007 and ended 31 
March 2010. University College London Hospital research ethics committee approved the 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
trial (MREC Reference 07/Q0505/57) and participants provided informed consent. We 
recruited from 24 rheumatology clinics in England and Wales. We included men and women 
aged over 18 with disease durations over 12 months who met the 1987 criteria for 
classification of rheumatoid arthritis and National Institute for Health and Care Excellence 
(NICE) criteria for starting biologics in England and Wales.[10] (Subsequent to our trial, NICE 
has recommended that biologics are used only if disease is severe and has not responded to 
intensive therapy with a combination of cDMARDs).[11] We excluded those unable or 
unwilling to give informed consent, had not had successful results with or had 
contraindications to all combinations of disease modifying drugs (including possible 
pregnancy), had contraindications to TNFis, had serious inter-current illness, or were taking 
high dose corticosteroids (>10 mg prednisolone). Safety monitoring followed national 
guidance. Before randomisation all patients had received two disease modifying drugs; 62 
had received three; 77 were taking combinations of two or more disease modifying drugs; 
and 24 were taking prednisone (mean dose 4 mg/day; range 1-7 mg). One hundred and 
sixty-two patients were receiving methotrexate at baseline (132 oral, 30 subcutaneous); the 
average dose was 18mg/week (range 5-25mg). Clinical characteristics of the sample, 
including use of medications, are reported in related publications [9, 12].  
 
The sample size was based on testing the null hypothesis of a difference of >0.22 (minimal 
clinically important change) on the Health Assessment Questionnaire between the two 
treatments. With a (one sided) testing level of 5%, we needed a sample size of 176 to 
achieve 90% power. We recruited 214 patients to allow for non-receipt of treatment or 
drop-outs. After screening for eligibility, consenting patients were randomised in blocks of 
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four with allocation stratified by region. MedSciNet generated the allocation sequence; trial 
staff had no prior knowledge of the allocation sequence.  
 
Patients allocated to the TNFi arm were given a particular TNFi depending on patient 
preference and local circumstances. Methotrexate was also given to patients on TNFis to 
maximise efficacy and reduce formation of antichimeric antibodies where necessary. 
Patients intolerant to methotrexate took another DMARD. TNFi patients had their TNFi 
stopped and another started for 3 reasons: poor response (Disease Activity Score reduction 
<1.2) at 3 or 6 months; adverse events from medication; or patient choice. Patients who 
failed two TNFis, and were not able to start a third, were offered a cDMARD. 
 
Patients allocated to the cDMARDs arm were given cDMARDs with proven efficacy over 
DMARD monotherapy. These included: triple therapy with methotrexate (methotrexate–
sulfasalazine–hydroxychloroquine); other methotrexate combinations (methotrexate–
ciclosporin, methotrexate–leflunomide and methotrexate–gold); and a sulfasalazine 
combination (sulfasalazine–leflunomide). Additional monthly steroids (intramuscular Depo-
Medrone (120 mg stat) or equivalent) were used if needed. cDMARDS were stopped for the 
same three reasons stated above for TNFis but poor response was judged at 6 months only. 
Patients with poor response at 6 months were offered TNFis. 
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Resource use data 
Trial medication use (name, dose, frequency and duration of use) was recorded 
prospectively on trial proformas by clinical and research staff over the entire study period. 
Other individual-level economic data were captured by self-report using an adapted Client 
Service Receipt Inventory (CSRI;[13] see Hurley et al.[14] and Patel et al.[15] for similar 
applications), by interviewer-completed survey at baseline, and 6 and 12 months post 
randomisation, covering the previous 3-months. This covered socio-demographic data; use 
of (all-cause) community and secondary-based health and social care services and other 
medications; lost pay from illness-related time off work; receipt of social security benefits.  
 
Costs 
Individual-level resource-use data, including trial medications, were multiplied by 
appropriate unit costs (supplementary appendices 1 and 2) to calculate a cost per 
participant. Using a detailed approach, medication unit costs were converted into cost per 
milligram (mg) based on the most cost-efficient pack size, choosing maintenance prices over 
initial treatment prices and generic prices over branded ones to obtain conservative 
estimates (supplementary appendix 2). Total costs were then computed at baseline, 6 
months and 12 months from three perspectives: health and social care perspective;  
societal, additionally including participant lost pay due to work absence; and a second 
societal, which further added social security benefits.  
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Trial medication costs were available for the full 0-6 and 7-12 month periods; all other costs 
represented data collection periods of 4-6 months and 10-12 months inclusive, so were 
doubled to represent 6-month periods. All costs are reported in English pounds sterling at 
2010/11 prices and can be converted to United States dollars ($) or Euros using the rates £1 
= 1.42 or £1 = 1.28 respectively (based on 2011 purchasing power parities which equalise 
the purchasing power of the currencies [16]). Discounting was unnecessary. 
 
Outcomes 
Cost-effectiveness analyses were based on the trial’s primary outcome measure, the Health 
Assessment Questionnaire (HAQ),[17] accounting for lower scores indicating better 
outcome. Cost-utility analyses were based on quality-adjusted life years (QALYs), estimated 
by applying appropriate general population utility weights (Brazier et al.[18]; Dolan et al.[19] 
to individual health statement measurements using both the Short-Form 36 (SF-36[20]) and 
the EuroQoL 5-Dimension measure (EQ-5D-3L[21] administered at baseline, 6 and 12 
months. QALY gains between baseline and 6 months, and between 6 months and 12 months 
were then calculated as the total area under the curve. 
 
Analyses 
Costs and outcomes were compared at 6 and 12 months and are presented as means and 
standard deviations. Mean differences between trial arms and 95% confidence intervals 
(CIs) were obtained using non-parametric bootstrap regressions (1000 repetitions). For cost 
comparisons, we included covariates for baseline cost from the same cost perspective, 
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baseline HAQ score, duration of illness, age, sex, region (a stratification factor in the 
randomisation process) and ethnicity. Outcome comparisons included covariates for 
baseline values of the same outcome plus baseline HAQ score, duration of illness, age, sex, 
region and ethnicity. 
 
An electronic data capture system (MedSciNet AB, Stockholm, Sweden; 
http://medscinet.com) was programmed to disallow individual-item non-response on the 
service use section of the CSRI. For non-trial medication and other societal impacts, we 
imputed missing values as necessary (supplementary appendix 3).   
 
We used available cases for each analysis. To explore the potential impact of excluding non-
responders we examined socio-demographic and clinical characteristics of responders 
versus the full sample and, in a sensitivity analysis, imputed missing 6- and 12-month total 
costs and outcomes using the multiple imputation command in Stata version 11.2.[22] 
Missing costs were imputed based on variables expected to predict total follow-up costs: 
baseline HAQ score, duration of illness, age, sex, region, ethnicity, trial arm and equivalent 
baseline cost (and equivalent cost at 6 months for 12-month imputations). Imputations of 
follow-up HAQ scores were based on baseline HAQ score, duration of illness, age, sex, 
region, ethnicity and trial arm (and HAQ score at 6 months for 12-month imputations). 
Imputations of missing QALYs were based on baseline HAQ score, duration of illness, age, 
sex, region, ethnicity, trial arm and equivalent baseline utility score (and utility score at 6 
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months for 12-month imputations). Resulting full sample cost and outcome data were 
analysed as per the main analyses. 
 
Cost-effectiveness and cost-utility analyses 
Accounting for the three cost perspectives and three outcomes, there were nine possible 
cost-outcome combinations to consider in the economic evaluation. Incremental cost-
effectiveness ratios (ICERs) were calculated only for combinations showing both significantly 
higher costs and better outcomes in either trial arm. 
 
Uncertainty around cost-effectiveness/cost-utility from a health and social care perspective 
was explored using cost-effectiveness acceptability curves (CEACs) based on the net-benefit 
approach[23] to present the probability that the cDMARDS arm is cost-effective compared 
with the TNFis arm for a range of values (from £0 and £50,000) that a decision-maker would 
be willing to pay for an additional QALY or an additional point improvement in HAQ score.  
 
Data were analysed using Stata version 11.2.[22] 
 
Trial registration 
ISRCTN (International Standard Registered Clinical/soCial sTudy Number) 37438295 
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RESULTS 
Response rates 
Two-hundred and five participants were recruited into the study: 101 into the TNFis arm 
and 104 into the cDMARDs arm. Details of trial medications are reported in related 
publications [9, 12]. Response rates to CSRI and outcome questionnaires and completion of 
trial medication data were 90% or above for all components at baseline and 6 and 12 
months and across both trial arms. 191 (93%) participants had both cost and outcome data 
at 6 month follow-up and 186 to 188 (91 to 92%) had both cost and outcome data at 12 
month follow-up. There were no notable differences in characteristics between the 
subsamples included in the available case analyses and the full sample (Table 1). 
 
Resource use 
Resource use (not tested statistically) was broadly comparable between groups (Table 2). 
General practitioner (GP) surgery visits, practice nurse surgery visits, repeat prescription 
requests and hospital outpatient appointments were common in both groups at all-time 
points, with other service use being relatively rare. The number of participants using non-
trial concomitant medications was also similar in both groups at all-time points. 
 
Costs 
Costs for both groups were equivalent at baseline (Table 3). Costs of social security benefits 
and lost income are small relative to health and social care costs. At 6 and 12 month follow-
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up, average values for cost categories remained equivalent between groups except for cost 
of trial medications, which was significantly lower in the cDMARDs arm (6-month adjusted 
mean difference −£3637, 95% CI −£3838 to −£3420; 12-month adjusted mean difference 
−£1894, 95% CI −£2320 to −£1427). The additional trial medication cost in the TNFis group 
overshadowed all other cost categories in that arm. The increase in trial medication costs 
between 6 and 12 months in the cDMARDs arm was due to a significant proportion of this 
group (n=46; 44%) switching to the more expensive TNFis at 6 months because of non-
response to cDMARDs by 6 months. Switching in the reverse direction was uncommon (a 
total of four participants), so trial medication costs in the TNFis arm did not fall a great deal 
between 6 and 12 months.  
 
The cDMARDs arm had significantly lower total costs from all perspectives at both follow-
ups. The difference is greater at 6 months than at 12 months because of the greater trial 
medication cost differential before switching taking place. Costs from both societal 
perspectives are similar to those from a health and social care perspective because of the 
dominance of trial medication costs. 
 
Outcomes 
At baseline, the cDMARDs arm had an advantage on utility scores estimated from the SF-36 
but this did not carry through as an advantage in (baseline-adjusted) utility scores at either 
of the follow-ups or in the resulting QALY estimates (Table 4). The cDMARDs arm did, 
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however, show advantages in terms of the HAQ and EQ-5D-3L based utility scores at 12 
months, although the latter did not translate into QALY advantages.  
 
Cost-effectiveness and cost-utility  
Based on the HAQ, the cDMARDs arm dominated with better outcomes and lower costs at 
12 months from all three perspectives. All other cost-outcome combinations similarly 
suggested that the cDMARDs strategy was preferable given equivalent outcomes were 
achieved at a significantly lower cost. CEACs showed high probabilities of cost-effectiveness 
for all examined cost-outcome combinations (Figure 1). Probabilities of cost-effectiveness at 
6 months based on the HAQ were noticeably reduced after reaching thresholds greater than 
£10,000 per point improvement, but were consistently high at 12 months. Sensitivity 
analyses based on imputed missing data produced the same conclusions. 
 
DISCUSSION 
 
Key Findings 
We show that, for patients with active RA who have failed to respond to methotrexate and 
another DMARD, starting treatment with cDMARDs produces similar HAQ and QALY 
outcomes at 6 months compared to starting treatment with TNFis, and is significantly 
cheaper (from all cost perspectives) largely due to the lower costs of cDMARD medications 
compared with TNFis. By 12 months, the cDMARD strategy has the advantage of statistically 
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significant better HAQ outcomes (−0.16, 95% CI −0.32 to −0.01) although the cost difference 
is smaller due to the large proportion (44%) of people switching from cDMARDs to TNFis. 
The HAQ improvement is not clinically significant, so the clinically relevant conclusion is that 
the cDMARDs strategy provides non-inferior clinical outcomes to the TNFis strategy, but at 
significantly lower cost to the health and social care system. Adverse events are fully 
described elsewhere [9] but it is worth noting that serious adverse events and withdrawals 
because of toxicity were equally common with cDMARDs and TNFis. The total number of 
adverse events (ranging serious to minor) was though higher with cDMARDs, mainly due to 
88 more adverse events related to the digestive system (148 vs. 60) and 20 more adverse 
events related to the nervous system (61 vs. 41).  
 
Strengths and Limitations 
This was a comprehensive and prospective economic evaluation, embedded within a 
robustly designed and implemented clinical trial with high follow-up rates. Other trials of 
cDMARDs have lacked such broad perspectives (e.g. Wailoo et al.[24]). The multi-centre 
design and broad cost perspective necessitated some self-report, risking recall bias; we 
mitigated such risk by restricting recall periods to 3 months but this then necessitated data 
extrapolation to generate data for a 6-month period, which may not accurately reflect any 
variations in service use and other economic impacts across the measured and non-
measured periods. Nevertheless, such biases are likely to be equivalent between arms and 
minimal given our finding that trial medication costs dominated total costs - these more 
influential medication data were available for the entire follow-up and were recorded 
prospectively by clinicians and the research team. Finally, we were unable to include 
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informal care costs and only report one-year outcomes as longer-term modelling was 
beyond the scope of this study.  
 
Comparison with other studies   
 
There is now extensive evidence that intensive treatment strategies involving conventional 
DMARDs and, to an extent, glucocorticoids, are cost-effective as well as beneficial in early 
RA [6,24,25]. In early RA, economic analyses from all three published head-to-head trials 
comparing cDMARD combinations with TNF inhibitors with methotrexate show biologic 
strategies are not cost-effective by conventional standards and that DMARDs are preferred. 
[26,27,28] For example, Eriksson et al.’s [27] examination of infliximab (TNFi) against 
conventional combination treatment reached similar conclusions of greater costs and lack of 
cost-effectiveness for the TNFi in a comparable trial-based economic evaluation covering 21 
months. The only other head-to-head trial in established RA (RACAT Trial[29]) similarly 
concludes as us that initiating biologics before triple therapy (combination cDMARDs) is not 
cost-effective. Using modelling, Stevenson et al. [30] argue that, in England, the cost-
effectiveness of biologics for RA is questionable and will only be economically worthwhile in 
those with the worst prognoses. 
 
The BeSt trial demonstrated that biologics might be cost-effective when accounting for lost 
productivity.[28] The DRESS trial concluded that optimising TNFi dosing - to titrate to lowest 
dose - offers substantial cost savings without clinically significant QALY detriments.[31] 
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More commonly, modelling-, rather than trial-, based studies have been used to justify the 
higher treatment cost of TNFis and other biologics by showing prevention of, or slowed, RA 
progression over longer time horizons. For example, Stephens et al. [32] examined 
combination adalimumab (TNFi) plus methotrexate (DMARD) versus methotrexate alone for 
people with early aggressive RA in a 30-year simulation based on data from a short-term 
clinical trial (PREMIER), concluding cost savings and thus cost-effectiveness when accounting 
for irreversible radiographic damage and lost productivity costs.  
 
However, recent reviews [33,34] highlight contradictory findings, methodological nuances 
and/or moderate to high cost-effectiveness ratios for biologics. For example, Joensuu et al.’s 
[34] systematic review (with quality assessment) of 41 cost-utility analyses included 21 
studies comparing biologics and cDMARDs in patients with insufficient response to 
cDMARDs. While incremental cost-effectiveness ratios appeared unrelated to study quality, 
they naturally varied by specific study features (e.g. sub-group, specific medications and 
comparators) or were contradictory. Against current cost-effectiveness thresholds, results 
broadly suggested that biologics lacked cost-effectiveness in treatment naive patients and 
patients with inadequate responsive to DMARDs. However, at higher thresholds of 50,000–
100,000 Euros/QALY, biologics might be cost-effective among cDMARD resistant patients. Of 
note, all except three of the studies reviewed by Joensuu et al. [34] were modelling studies 
(using multiple data sources including trials and registries). 
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Modelling approaches are helpful when pursued with care [35,36] but can carry challenges 
and limitations. For example, Heather et al. [37] found that only one fifth of model-based 
economic evaluations of TNFis they reviewed accounted for adverse drug event costs (and 
not always with transparency on how this was done) which may bias cost-effectiveness 
estimates for TNFis. Trials that assess a range of resource use inherently include such effects 
if the follow up period is of sufficient duration, as is the case here. Further, Tosh et al.’s [38] 
review of how RA treatment sequencing has been modelled suggested weaknesses in 
underlying evidence and in methods reporting, again generating cost-effectiveness 
uncertainty. Treatment decisions for people with RA can be complex, in practice and for 
modelling.[39] Tran-Duy et al. [39] used observational data to inform a simulation of long 
term outcomes and cost-effectiveness of (a Dutch clinical guideline-informed) treatment 
strategy where both DMARDs and biological response modifiers (BRMs) are available 
against a strategy without BRMs. They suggested their flexible modelling approach could 
helpfully incorporate factors that determine disease progression, costs and outcomes, 
although their simulated ICER for the strategy including BRMs exceeded conventional 
thresholds for cost-effectiveness.  
 
There is thus a mixed picture of cost-effectiveness for RA treatment. Models remain reliant 
on high quality trial-based or observational evidence to underpin estimates of short-term 
treatment response; our high quality trial can usefully inform future such studies. There 
remains uncertainty about the relative cost-effectiveness of different drugs within each 
class due to a paucity of head to head comparisons.[40,41,42] Treatments also continue to 
evolve. Substantially cheaper biosimilars are now becoming available; these can drive down 
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the costs of original drugs and modelling studies in countries where they have been used 
suggest they will improve the cost-effectiveness of these treatments,[43] though the way 
this will impact upon the routine clinical use of biologics in RA is not yet fully known. 
 
CONCLUSION 
This economic evaluation suggests that for patients with established RA who have failed to 
respond to methotrexate and another DMARD, beginning treatment with cDMARDs is a 
more cost-effective treatment approach, since it provides equivalent outcomes to starting 
treatment with TNFis and either avoids or delays additional costs associated with the more 
expensive TNFis. This offers a pragmatic response to financial challenges presented by new 
and more expensive treatments.  
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Table 1: Characteristics of full sample and sub-sample with costs and HAQ, EQ-5D-3L and SF-36 
 Full sample  
 
Sub-sample with 6month 
cost and HAQ / EQ-5D-3L 
/ SF-36 data  
Sub-sample with 12 month 
cost and EQ-5D-3L data  
Sub-sample with 12 month 
cost and HAQ / SF-36 data  
 (n=205)  (n=191)  (n=186) (n=188)  
 n % N % N % n % 
Gender:           
Male  53 26 45 24 45 24 46  25 
Female 152 74 146 76 141 76 142 76 
Ethnicity:          
White  181 88 168 88 162 87 164 87 
Other 24  12 23  12 24 13 24  13 
Region:         
London & South 128 62 127 67 121 65 121 64 
Midlands  16  8 13  7 11  6 13 7 
North  61  30 51  27 54  29 54 29 
 Mean Standard 
deviation 
Mean Standard 
deviation 
Mean Standard 
deviation 
Mean Standard 
deviation 
Age  57.34 11.97 57.11 11.94 56.84  12.08 56.91 12.02 
Duration of illness in 
years 
8.20 8.82 8.35 8.98 8.25  8.92 8.24 8.88 
HAQ at baseline 1.85 0.63 1.86 0.63 1.85  0.64 1.85 0.64 
EQ-5D-3L based utility 
at baseline 
0.37 0.31 0.37 0.31 0.37 0.31 - - 
SF-36 based utility at 
baseline 
0.54 0.11 0.54 0.11 - - 0.54 0.11 
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Table 2: Resource use at 6 and 12 month follow-up (for the previous 3 months)  
  6 months 12 months 
  TNF (n=97) DMARDS (n=94) TNF (n=93) DMARDS (n=95) 
 Unit Number 
of users 
Mean*  SD Number 
of users 
Mean*  SD Number 
of users 
Mean* SD Number 
of users 
Mean*  SD 
GP              
At surgery Visit 55 2 1 42 2 1 58 2 2 60 2 1 
At home Visit 3 2 1 2 1 <1 3 1 1 4 2 1 
Phone call Call 14 1 1 9 2 1 13 1 1 16 1 1 
Repeat 
prescription 
request without 
GP contact 
Prescription 70 3 1 63 3 1 61 2 1 68 3 2 
Nurse              
At surgery Visit 31 3 4 31 3 3 31 2 2 24 2 1 
Phone call Call 2 1 <1 2 2 1 5 2 1 2 1 <1 
Physiotherapist              
At hospital therapy unit 4 3 1 8 4 3 7 3 2 11 5 6 
At home Visit 0 - - 0 - - 0 - - 0 - - 
At GP surgery Visit 1 1 - 2 3 <1 2 3 3 1 8 - 
Elsewhere Visit 2 2 1 0 - - 1 2 - 1 1 - 
Occupational 
therapist 
             
At hospital therapy unit 3 1 1 4 2 1 1 1 - 6 2 1 
At home Visit 4 1 <1 2 1 <1 1 1 - 1 1 - 
At GP surgery Visit 0 - - 0 - - 0 - - 0 - - 
Elsewhere Visit 0 - - 1 1 - 1 3 - 1 1 - 
Hospital services              
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A&E Visit 9 1 <1 4 1 <1 5 1 1 10 1 <1 
Hospital stay Night 5 7 5 4 4 5 2 11 13 5 2 1 
Outpatient  appointment 58 3 1 55 3 2 55 3 2 56 2 1 
Social services              
Meals on wheels Meal 0 - - 1 60 - 0 - - 0 - - 
Home help  Visit 2 46 63 1 1 - 3 31 51 0 - - 
Social worker Hour 3 1 1 3 1 1 2 2 <1 1 1 - 
Social worker 
phone call 
contact 1 3 - 1 2 - 1 1 - 2 2 1 
Other health or 
social service 
service 3 14 11 3 31 51 2 1 <1 2 19 16 
Non-trial 
medication 
n/a 94 - - 88 - - 91 - - 90 - - 
 
*Mean for users only 
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Table 3: Summary costs at baseline, 6 and 12 months (for the previous 3 months)  
  TNF  
n=101 
 DMARDs 
n=104 
Unadjust
ed mean  
95% C.I. $ Adjusted 
mean  
95% C.I.$$ 
 valid 
n 
Mean  
£ 
SD valid 
n 
Mean 
£ 
SD differenc
e$ 
 differenc
e$$ 
 
           
Costs at baseline (previous 3 months)           
Health & social care, excluding trial 
medication** 
101 736 1082 104 601 476 -131 -379 to 97 - - 
Lost pay** 101 60 262 104 84 440 24 -66 to 131 - - 
Social security benefits** 101 71 76 104 63 67 -9 -29 to 12 - - 
Costs at 6 months (previous 3 months)           
Health & social care, excluding trial 
medication** 
97 536 947 94 511 705 -27 -262 to 
202 
6 -217 to 206 
Lost pay** 97 71 405 94 35 310 -35 -127 to 67 -35 -115 to 59 
Social security benefits** 97 77 75 94 74 77 -2 -21 to 21 3 -15 to 19 
Trial medication costs*** 97 4166 1012 97 510 356 -3660* -3855 to -
3432 
-3637* -3838 to -
3420 
Costs at 12 months (previous 3 months)           
Health & social care, excluding trial 
medication** 
95 659 1699 93 583 634 -74 -486 to 
255 
-24 -363 to 230 
Lost pay** 93 19 132 95 2 18 -16 -46 to 2 -17 -42 to 2 
Social security benefits** 93 85 83 95 77 84 -6 -32 to 16 5 -12 to 23 
Trial medication*** 96 3546 1631 94 1547 1547 -1988* -2458 to -
1555 
-1894* -2320 to -
1427 
Total costs extrapolated to 6 months           
Costs at 6 months (previous 6 months           
Health & social care perspective, including 
trial medication  
97 5238 2093 94 1538 1393 -3703* -4175 to -
3199 
-3615* -4104 to -
3182 
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Societal perspective, including trial 
medication, excluding social security 
benefits 
97 5379 2236 94 1607 1569 -3774* -4298 to -
3230 
-3683* -4198 to -
3195 
Societal perspective,  including trial 
medication, including social security 
benefits 
97 5533 2241 94 1755 1591 -3778* -4303to -
3230 
-3684* -4199 to -
3194 
Costs at 12 months (previous 6 months)           
Health & social care, including trial 
medication  
93 4866 3147 95 2718 1890 -2129* -2941 to -
1417 
-1930* -2599 to -
1301 
Societal, including trial medication, 
excluding social security benefits 
93 4904 3218 95 2722 1890 -2162* -2977 to -
1449 
-1974* -2648 to -
1334 
Societal, including trial medication, 
including social security benefits 
93 5073 3208 95 2876 1914 -2175* -2991 to -
1465 
-1977* -2644 to -
1338 
 
$Comparisons include a covariate for region  
$$Comparisons include covariates for equivalent baseline cost, baseline HAQ, duration of illness, age, gender, region and ethnicity  
* Statistically significant 
 ** 3-month costs 
 *** 6-month costs 
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Table 4: HAQ and QALY outcomes at baseline, 6 and 12 months 
 
 TNF DMARDs Unadjusted 
mean  
95% C.I. Adjusted 
mean  
95% C.I.$ 
 valid n Mean SD valid n Mean SD difference$  difference$$  
Utilities and 
HAQ 
          
Baseline           
SF-36 utility 101 0.52 0.11 104 0.56 0.10 0.04 0.01 to 0.07 - - 
EQ-5D-3L 
utility 
101 0.35 0.31 104 0.39 0.31 0.04 -0.04 to 0.12 - - 
HAQ  101 1.90 0.67 104 1.80 0.59 -0.10 -0.28 to 0.07 - - 
6 months           
SF-36 utility 97 0.59 0.13 94 0.62 0.12 0.03 -0.01 to 0.06 0.00 -0.03 to 0.03 
EQ-5D-3L 
utility 
97 0.53 0.30 94 0.56 0.26 0.03 -0.05 to 0.10 -0.01 -0.08 to 0.06 
HAQ  97 1.55 0.83 94 1.52 0.65 -0.03 -0.22 to 0.19 0.07 -0.08 to 0.21 
12 months           
SF-36 utility 94 0.60 0.14 94 0.64 0.13 0.04 0.01 to 0.08 0.03 -0.00 to 0.07 
EQ-5D-3L 
utility 
93 0.50 0.31 94 0.60 0.28 0.10 0.02 to 0.19 0.10 0.02 to 0.18* 
HAQ  94 1.60 0.84 95 1.33 0.77 -0.27 -0.51 to -0.04 -0.16 -0.32 to -0.01* 
QALYs           
6 months           
SF-36 QALYs 97 0.28 0.05 94 0.30 0.05 0.02 0.00 to 0.03 0.00 -0.01 to 0.01 
EQ-5D-3L 
QALYs 
97 0.22 0.14 94 0.24 0.12 0.02 -0.02 to 0.05 0.00 -0.02 to 0.02 
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12 months           
SF-36 QALYs 93 0.30 0.06  87 0.32 0.05 0.02 -0.00 to 0.03 0.01 -0.00 to 0.02 
EQ-5D-3L  
QALYs 
92 0.26 0.13 88 0.29 0.11 0.03 -0.01 to 0.06 0.02 -0.01 to 0.05 
 
$Comparisons include a covariate for region 
$Comparisons of HAQ  include covariates for baseline HAQ, duration of illness, age, gender, region and ethnicity; comparisons of utilities and 
QALYs include covariates for appropriate baseline utility, baseline HAQ, duration of illness, age, gender, region and ethnicity  
*Statistically significant 
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Figure 1: Cost-effectiveness acceptability curves at 6 and 12 months from a health and social 
care perspective for all outcomes: a) HAQ; b) SF-36; and c) EQ-5D-3L.*  
 
 
